Our results show that the addition of IL-2 and IL-12 enables more potent responses to RT and checkpoint blockade for moderately immunogenic MC38 and CT26 colon adenocarcinomas, relatively cold B78 melanoma, and very cold 9464D-GD2 neuroblastoma. The gene discussed is IL2; the disease is neuroblastoma.